HLA-II-Associated HIV-1 Adaptation Decreases CD4 <sup>+</sup> T-Cell Responses in HIV-1 Vaccine Recipients-Reference-Cited by-同舟云学术

HLA-II-Associated HIV-1 Adaptation Decreases CD4 ⁺ T-Cell Responses in HIV-1 Vaccine Recipients

Published:2022-09-14 Issue:17 Volume:96 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Files Jacob K.¹^ORCID,Sterrett Sarah¹,Henostroza Sebastian¹,Fucile Christopher²,Maroney Kevin¹,Fram Tim¹,Mallal Simon³⁴,Kalams Spyros³^ORCID,Carlson Jonathan⁵,Rosenberg Alexander²⁶,Erdmann Nathan¹,Bansal Anju¹^ORCID,Goepfert Paul A.¹⁶

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

2. Informatics Institute, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

3. Vanderbilt University Medical Center, Nashville, Tennessee, USA

4. Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia

5. Microsoft Research, Microsoft, Redmond, Washington, USA

6. Department of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

Abstract

Despite decades of research, an effective HIV-1 vaccine remains elusive. Vaccine strategies leading to the generation of broadly neutralizing antibodies are likely needed to provide the best opportunity of generating a protective immune response against HIV-1.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.01191-22

Reference45 articles.

1. Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection

2. Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

3. Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study)

4. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

5. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine